AKT1 and neoplasm: In vivo preclinical studies have also shown that SGK1 KD in PC-3 xenografts significantly reduces tumor burden and metastatic potential compared to controls [265], and combining SGK and AKT inhibitors (e.g., 14h and MK-2206) is synergistic in both breast and thyroid cancer models [257,266,267].